The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
New blood biomarker data from Eli Lilly, Roche and Alamar Biosciences headline a London conference where non-amyloid mechanisms …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
Already a subscriber? Log in